Sanofi US News

Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide

- Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children -

- Largest supplier of influenza vaccine in U.S., first to ship, will distribute more than 60 million doses of flu vaccines for fall immunization campaigns -

- EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus® -

-- Lixisenatide decreased HbA1c by reducing PPG when added to basal insulin with or without oral anti-diabetic agents --

- Headfirst! Expert Advice on Lice Offers Moms and Healthcare Providers Helpful Tools and Resources to Overcome Head Lice -

- "Get in the Game" urges parents to take action and vaccinate against meningococcal disease in advance of the upcoming sports season

New Fluzone® Quadrivalent (Influenza Virus Vaccine):

Campaign Continues to Educate Adults on How to Help Protect Themselves and How to Help Stop the Spread of Pertussis to Infants

- Connect & Coach™ Awarded $100,000 to Further Develop its Novel Solution to Help Improve Health Outcomes for People Living with Diabetes -

- Bettis Unveils New Playbook for Defending Against Severe Allergic Reactions and Urges Those Affected to Take Action -

The same trusted formula in an easy aim spray

-Donation to Diabetes Hands Foundation Doubled When Documentary Reaches 10,000 Views-

Growth platforms(2) sales increased 8.6%(3)

Donation to fund instrumentation and scholarships for university science and technology programs

Over-the-Counter Allergy Brand Now Offers Topical Relief for Itchy, Dry Skin Just in Time for Summer

Game On! Leslie and Sanofi's Chattem Encourage Families to Put Seasonal Allergies Behind Them and Stay Active This Spring

National Patient Spokesperson Melanie Bloom Commemorates Significant Achievements to Raise Awareness of DVT and Potentially Fatal Complication, Pulmonary Embolism

Pathway to Stop Diabetes to provide funding for innovative diabetes researchers

- Sanofi US to Donate Up to $100,000 to Patient Organizations -

- Bettis and Miller, Both at Risk for Anaphylaxis, Join Forces with Sanofi US to Introduce Auvi-Q (Epinephrine Injection, USP) and Serve Up Allergy-Friendly Tips for Big Game Parties -

--LeGoo® proprietary gel technology provides clear surgical field for cardiothoracic and vascular surgeons without trauma to blood vessels--

-- Breakthrough device design talks patients and caregivers through the injection process --

- NBA All-Stars Andre Iguodala and Danny Granger and Seven-Time WNBA All-Star Tamika Catchings to Help Raise Awareness about Diabetes -

-- Product acquisition further strengthens Consumer Healthcare Division of Sanofi US --

- Company’s annual Adopt-a-Family drive delivers essential items to local families in need -

- Registries for All Diseases wins $300k to create crowdsourced cross-disease registry -

Pathway to Stop Diabetes to Provide Funding for Innovative Diabetes Researchers

- New Data Presented at American Society of Hematology Annual Meeting Show Activity Against Disease and Symptom Alleviation -

Response Includes Contribution to Three New Jersey Area Organizations

- Two-Dose Series Given at Regularly Scheduled Pediatric Visits Demonstrates Strong Immune Responses -

Growth Platforms(2) reached over 70% of sales

- QIV is the next evolution of influenza vaccine designed to help protect against influenza B, a significant cause of influenza illness and associated complications across all ages, and especially children -

– CDC analysis of 10 influenza seasons indicates use of a four-strain vaccine could have prevented 2.7 million influenza cases, 21 thousand influenza-related hospitalizations and almost 1,400 influenza-related deaths(1) –

Establishment of joint project teams will leverage strengths of academic and industry cross-organizational expertise in all stages of translational research

U.S. Senator Robert P. Casey, Jr. and Former First Lady Of Pennsylvania Ellen Casey Co-Chair Event

- Goal is to select novel clinical development candidates to help stop the global pandemic -